| scholarly article | Q13442814 |
| P50 | author | David J. Brooks | Q38329590 |
| Federico Turkheimer | Q41330642 | ||
| Paola Piccini | Q64856193 | ||
| Marios Politis | Q64856266 | ||
| Clare Loane | Q122914799 | ||
| P2093 | author name string | Kit Wu | |
| Peter Bain | |||
| Lorenzo Kiferle | |||
| Sophie Molloy | |||
| P2860 | cites work | "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease | Q28318197 |
| Estimation of the number of "true" null hypotheses in multivariate analysis of neuroimaging data | Q30648196 | ||
| Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next? | Q33761790 | ||
| Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models | Q33956111 | ||
| Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study | Q34160601 | ||
| Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. | Q34406533 | ||
| Concentrations and effects of buspirone are considerably reduced by rifampicin | Q35802991 | ||
| Distribution volume ratios without blood sampling from graphical analysis of PET data | Q36817029 | ||
| Buspirone in the treatment of levodopa induced dyskinesias | Q36946985 | ||
| Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. | Q37103028 | ||
| Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations | Q39119568 | ||
| Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial | Q40271567 | ||
| Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake | Q40602965 | ||
| L-Dopa-Induced Release of Cerebral Monoamines | Q41522173 | ||
| Buspirone in levodopa-induced dyskinesias | Q42285208 | ||
| Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. | Q42477740 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants | Q42997555 | ||
| L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia | Q43202012 | ||
| Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. | Q43794820 | ||
| Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias | Q45030408 | ||
| Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? | Q45274909 | ||
| Hypothalamic involvement in Huntington's disease: an in vivo PET study | Q45291041 | ||
| Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia | Q46294946 | ||
| Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. | Q46490885 | ||
| Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. | Q46546576 | ||
| Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease | Q46935041 | ||
| The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy | Q48144715 | ||
| Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats | Q48192232 | ||
| Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning | Q48210282 | ||
| Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats | Q48234068 | ||
| Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model | Q48270157 | ||
| In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. | Q48461720 | ||
| Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. | Q48546793 | ||
| Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. | Q48576080 | ||
| Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. | Q51832640 | ||
| Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. | Q53223116 | ||
| Peripheral pharmacokinetic parameters of levodopa/carbidopa and the on-off phenomenon in parkinsonian patients | Q68467884 | ||
| Effects of L-dopa on efflux of cerebral monoamines from synaptosomes | Q71771056 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| patient | Q181600 | ||
| levodopa | Q300989 | ||
| dyskinesia | Q629444 | ||
| P304 | page(s) | 1340-1349 | |
| P577 | publication date | 2014-02-17 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients | |
| P478 | volume | 124 |
| Q58598324 | A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein |
| Q36972794 | A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. |
| Q48113961 | Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse |
| Q60955074 | Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model |
| Q48867898 | Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. |
| Q40790760 | Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate. |
| Q91867899 | Blood Flow and Glucose Metabolism Dissociation in the Putamen Is Predictive of Levodopa Induced Dyskinesia in Parkinson's Disease Patients |
| Q45740164 | Cell Therapy for Parkinson's Disease |
| Q93138854 | Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation |
| Q38255967 | Central pharmacokinetics of levodopa: Lessons from imaging studies |
| Q52322702 | Cerebral serotonin transporter measurements with [11C]DASB: A review on acquisition and preprocessing across 21 PET centres. |
| Q38793660 | Chemical anatomy of pallidal afferents in primates. |
| Q41566638 | Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients |
| Q48335181 | Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? |
| Q38658203 | Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease |
| Q34557860 | Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist |
| Q39125374 | Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states |
| Q64765374 | Dyskinesia in multiple system atrophy and progressive supranuclear palsy |
| Q50079431 | Dyskinesias and levodopa therapy: why wait? |
| Q39075710 | Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. |
| Q98180940 | Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-α levels |
| Q27303857 | Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study |
| Q53410082 | Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. |
| Q38242091 | Emerging drugs for levodopa-induced dyskinesia |
| Q37277039 | Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia |
| Q26765499 | Foetal Cell Transplantation for Parkinson's Disease: Focus on Graft-Induced Dyskinesia |
| Q35053960 | Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats |
| Q64786852 | Functional imaging correlates of akinesia in Parkinson's disease: Still open issues |
| Q64785657 | Imaging Markers of Progression in Parkinson's Disease |
| Q31119042 | Imaging in Parkinson's disease. |
| Q41684008 | Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications |
| Q39324877 | Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias |
| Q47112234 | L-Dopa and Brain Serotonin System Dysfunction |
| Q40379397 | Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs |
| Q40696539 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q38355582 | Molecular imaging of levodopa-induced dyskinesias. |
| Q31158920 | Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. |
| Q50558839 | Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. |
| Q47344907 | Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias |
| Q30868628 | Neuroimaging in Parkinson disease: from research setting to clinical practice |
| Q39015987 | Neuroimaging in Parkinson's disease: a future perspective |
| Q28387732 | Neuroimaging of Parkinson's disease: Expanding views |
| Q28069529 | Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders |
| Q64759312 | Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders |
| Q34443682 | New treatments for the motor symptoms of Parkinson's disease |
| Q38845546 | Nondopaminergic treatments for Parkinson's disease: current and future prospects |
| Q30389213 | On the Complexity of Brain Disorders: A Symptom-Based Approach |
| Q42369736 | PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease |
| Q87460618 | Parkinson disease: A role for serotonergic neurons in levodopa-induced dyskinesia |
| Q46354756 | Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy |
| Q53442110 | Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers. |
| Q21129423 | Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications |
| Q48006992 | Quantitative profiling of neurotransmitter abnormalities in brain, cerebrospinal fluid, and serum of experimental diabetic encephalopathy male rat. |
| Q30916063 | Recent imaging advances in neurology. |
| Q64901815 | Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. |
| Q60907864 | Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia |
| Q48112379 | Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia |
| Q55050175 | Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. |
| Q48345542 | Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias. |
| Q92959120 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study |
| Q93197397 | Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review |
| Q48300577 | Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. |
| Q38218100 | Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations. |
| Q42483704 | Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys |
| Q39055550 | Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies |
| Q34795714 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. |
| Q26768220 | Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link? |
| Q48425550 | Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. |
| Q47202895 | The Protective Action Encoding of Serotonin Transients in the Human Brain |
| Q88150069 | The missing, the short, and the long: Levodopa responses and dopamine actions |
| Q89713007 | The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets |
| Q52685607 | The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective. |
| Q48372783 | The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. |
| Q33807060 | Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression |
| Q28078271 | What Mechanisms Are Responsible for the Reuptake of Levodopa-Derived Dopamine in Parkinsonian Striatum? |
| Q38951947 | l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements? |
Search more.